Drug Delivery Technology: Revolutionizing Cancer Therapies

Published Date: 01/05/2007
Category: Drug Delivery & Devices

Research Report Decription

Sample Pages:

Click here (PDF)

This report gives in depth analysis of innovative drug delivery technologies that are being applied to both innovative cancer therapies and those that are currently in use. Innovative parenteral, oral and transdermal delivery technologies are considered in the report and forecasts given of the sales of products incorporating these technologies.

Key Questions Answered:

• How will the drug delivery technology drivers change in the cancer arena in the next decade and beyond?
• What are the key delivery technologies in the oncology field?
• When are products which utilise these key delivery technologies likely to reach the market?
• Which companies are the winners in each technology category?
• How are drug delivery technologies evolving to meet the demands of the oncology market?
• Where are the market opportunities now and in the future?

• What do we predict will be the value of the cancer drug delivery market each year until 2012, in 2015 and in 2020?

Companies Mentioned:

Ablynx, Abraxis BioSciences, Access Pharmaceuticals, Acusphere, Adherex, Adhesives Research, AlphaVax, ALZA, Amgen, AstraZeneca, Avidimer Therapeutics, BioDelivery Sciences International, BioProgress, BioVation, Bristol-Myers Squibb, Cell Therapeutics, Cephalon, Corixa, Daiichi, Debiopharm, DelSite Biotechnologies, Delth Systems, Dianisco, Diatos, DOR BioPharma, Eli Lilly, Emisphere Technologies, Enzon Pharmaceuticals, ExpressionGenetics (EGEN), Genencor, Genentech, Generex Biotechnology, GSK, Guilford, Hana Biosciences, Hanmi Pharmaceuticals, MIT, IDEA, ImClone, INEX Pharmaceutical, Inovio BioMedical Corporation, Institut Pasteur, Labopharm, Light Sciences, Lipoxen, MaxCyte, Merck Serono, Millennium, Miravant, Mountain View Pharmaceuticals, Murus, Nektar Therapeutics, NeoPharm, Neurotech, Nippon Kayaku, Nitto Denko Technical Corporation, NOF Corporation, Norwood Immunology, Novartis, Oakwood Laboratories, OctoPlus, Pfizer, PGXTL, Protherics, QLT Inc, Roche, sanofi-aventis, Schering AG, Seattle Genetics, SkyePharma, Sonus Pharmaceuticals, Starpharma, SunBio, Supratek, TAP, UCB, Valentis, Valera Pharmaceuticals, Ventaria Pharmaceuticals, Wyeth

Paper Highlights:

• 2006 global oncology market worth nearly US$33 billion.
• The market has attracted attention of big pharma players such as AstraZeneca, BMS, Lilly, GSK, Merck Serono, Novartis, Pfizer, Roche/Genentech, sanofi-aventis & TAP.
•  >650 products in clinical development however; 4 key challenges remain - ensuring efficient drug delivery, avoiding systemic toxicity & resistance, and improving specificity.
• Analysis of historic (2000-2005) market trends of the oncologypharmaceutical sales and advanced drug delivery sales.

• Forecasts for near-term (2006-2012) and the future (2020) market growth assessed based on the technology platforms evaluated in the report.

• Plus, sales forecasts for approved and pipeline oncology products used as a basis for our oncology drug delivery sales (ODDS) forecasts.
• Drug delivery companies applying a plethora of platforms, including passive and targeted systems, to overcome the above challenges.
• Increasingly multifunctional systems being applied to overcome pharmacodynamic issues and targeted delivery in a single solution.
• Many revamped products will reach the market over the next 6 years, driving future market growth. Their success is analyzed in detail and case studies provided to highlight the progress of each technology.

• As the oncology market evolves and patients are diagnosed and treated earlier during the course of the disease, both in the post-adjuvant and neo-adjuvant setting, the need for oral agents will grow. Several drug delivery companies are working towards this goal including: Access, ALZA, Emisphere and Labopharm. Each has adopted a different strategy and all are analyzed in detail.